ES2981584T3 - Proceso para la fabricación de 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo - Google Patents

Proceso para la fabricación de 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo Download PDF

Info

Publication number
ES2981584T3
ES2981584T3 ES17152400T ES17152400T ES2981584T3 ES 2981584 T3 ES2981584 T3 ES 2981584T3 ES 17152400 T ES17152400 T ES 17152400T ES 17152400 T ES17152400 T ES 17152400T ES 2981584 T3 ES2981584 T3 ES 2981584T3
Authority
ES
Spain
Prior art keywords
compound
cancer
inhibitor
chk1
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17152400T
Other languages
English (en)
Spanish (es)
Inventor
Ian Collins
Thomas Peter Matthews
Da Fonseca Mchardy Tatiana Faria
James Osborne
Michael Lainchbury
Michael Ian Walton
Michelle Dawn Garrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Application granted granted Critical
Publication of ES2981584T3 publication Critical patent/ES2981584T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES17152400T 2012-05-15 2013-05-14 Proceso para la fabricación de 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo Active ES2981584T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261647200P 2012-05-15 2012-05-15

Publications (1)

Publication Number Publication Date
ES2981584T3 true ES2981584T3 (es) 2024-10-09

Family

ID=48468659

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17152400T Active ES2981584T3 (es) 2012-05-15 2013-05-14 Proceso para la fabricación de 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo
ES13723910.9T Active ES2624307T3 (es) 2012-05-15 2013-05-14 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13723910.9T Active ES2624307T3 (es) 2012-05-15 2013-05-14 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo y usos terapéuticos del mismo

Country Status (19)

Country Link
US (3) US9663503B2 (enExample)
EP (2) EP2855448B1 (enExample)
JP (2) JP6027230B2 (enExample)
KR (6) KR102246265B1 (enExample)
CN (2) CN106279142B (enExample)
AU (2) AU2013261605B2 (enExample)
BR (1) BR112014026801B1 (enExample)
CA (1) CA2870837C (enExample)
DK (1) DK2855448T3 (enExample)
ES (2) ES2981584T3 (enExample)
IL (1) IL235133A (enExample)
IN (1) IN2014DN09221A (enExample)
MX (1) MX358819B (enExample)
NZ (1) NZ702050A (enExample)
PL (1) PL2855448T3 (enExample)
RU (1) RU2659786C2 (enExample)
SG (1) SG11201407238VA (enExample)
WO (1) WO2013171470A1 (enExample)
ZA (1) ZA201408452B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010938A2 (pt) 2011-11-09 2017-05-16 Cancer Res Tech Ltd compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico
MX358819B (es) 2012-05-15 2018-09-05 Cancer Research Tech Ltd 5-[[4-[[morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]am ino]pirazina-2-carbonitrilo y usos terapeuticos del mismo.
FI4190786T3 (fi) 2012-12-07 2025-05-23 Vertex Pharma Atr-kinaasin estäjinä käyttökelpoisia yhdisteitä
EP2970286A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP3077397B1 (en) 2013-12-06 2019-09-18 Vertex Pharmaceuticals Inc. 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
HRP20200186T1 (hr) 2014-06-05 2020-05-29 Vertex Pharmaceuticals Inc. Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja) * 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｃｈｋ１阻害剤とａｔｒ阻害剤との組み合わせを使用してがんを処置する方法
EP3355926B1 (en) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
WO2018094325A1 (en) * 2016-11-18 2018-05-24 The Trustees Of Columbia University In The City Of New York Therapeutic modulation of oncogenes by pharmacologic top2 targeting for cancer
CN110678169A (zh) * 2017-03-31 2020-01-10 西雅图遗传学公司 Chk1-抑制剂与weel-抑制剂的组合
WO2018191299A1 (en) * 2017-04-10 2018-10-18 Sierra Oncology, Inc. Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth
CN110582490A (zh) * 2017-04-10 2019-12-17 塞拉肿瘤学公司 抑制肿瘤生长的CHK1(SRA737)/PARPi组合方法
EP3631444A4 (en) * 2017-06-01 2021-06-09 Sierra Oncology, Inc. BIOMARKERS AND PATIENT SELECTION STRATEGIES
CN107266897B (zh) * 2017-08-04 2019-05-14 上海跃贝新材料科技股份有限公司 一种低粘度矿物增强pc/pet合金材料及其制备方法
AU2019224164A1 (en) * 2018-02-26 2020-10-01 Crt Pioneer Fund Lp Methods of treatment of cancer comprising Chk1 inhibitors
CN113631179A (zh) * 2019-01-25 2021-11-09 努梅迪公司 用于治疗特发性肺纤维化的方法
WO2020198510A1 (en) * 2019-03-28 2020-10-01 Sierra Oncology, Inc. Methods of treating cancer with chk1 inhibitors
CA3140123A1 (en) * 2019-05-14 2020-11-19 Sierra Oncology, Inc. Methods of treating cancer using chk1 inhibitors
CN110872277B (zh) * 2019-11-14 2021-06-04 浙江大学 N-取代芳环-2-氨基嘧啶类化合物及用途
CN110680928B (zh) * 2019-12-06 2020-04-28 深圳前海港影生物科技有限公司 抑制黑色素合成的偶联物及其在药品和化妆品中的应用
CN110684083B (zh) * 2019-12-06 2020-05-15 北京诺赛启研再生医学研究院有限公司 抑制黑色素合成的偶联物ii及其在药品和化妆品中的应用
TW202204348A (zh) * 2020-04-07 2022-02-01 美商西爾拉癌症醫學公司 Ｃｈｋ１抑制劑之合成方法
US20240351992A1 (en) * 2021-08-17 2024-10-24 Glaxosmithkline Intellectual Property (No.3) Limited Preparation of p2x3 antagonist
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773778A (en) 1972-01-24 1973-11-20 Squibb & Sons Inc Sulfur derivatives of pyrazolo (3,4-b)pyridines
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
NZ312665A (en) 1995-07-06 1999-08-30 Novartis Ag Rrolopyrimidines(7h-pyrrolo[2,3-d]pyrimidine and preparation of these
DE60221866T2 (de) 2001-10-19 2008-05-29 Ortho-Mcneil Pharmaceutical, Inc. 2-PHENYL BENZIMIDAZOLE UND IMIDAZO-i4,5ö-PYRIDINE ALS CDS1/CHK2-INHIBITOREN UND ADJUVANTIEN IN DER CHEMOTHERAPIE ODER STRAHLUNGSTHERAPIE ZUR BEHANDLUNG VON KREBS
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
JP2005515173A (ja) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト ピリミド［４，５−ｂ］インドール誘導体
CA2484209C (en) 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
WO2003101444A1 (en) * 2002-05-29 2003-12-11 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
BRPI0413005A (pt) 2003-07-29 2006-09-26 Irm Llc compostos e composições como inibidores da proteìna cinase
EP1673343A4 (en) 2003-10-08 2008-09-10 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
DK1678166T3 (da) 2003-10-14 2009-11-09 Univ Arizona State Proteinkinaseinhibitorer
KR20070029110A (ko) 2003-10-16 2007-03-13 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암의 치료를 위한 ｒａｆ 키나아제의 저해제로서2,6-디치환 퀴나졸린, 퀴녹살린, 퀴놀린 및 아이소퀴놀린
US20050096324A1 (en) 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
CA2561831A1 (en) 2004-04-13 2005-12-22 Icagen, Inc. Polycyclic pyrazines as potassium ion channel modulators
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
MX2007013624A (es) 2005-04-28 2008-02-12 Supergen Inc Inhibidores de proteina cinasa.
KR101327780B1 (ko) 2005-06-28 2013-11-11 사노피 Ｒｈｏ 키나제 억제제로서의 이소퀴놀린 유도체
TW200804345A (en) 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
AR056206A1 (es) 2005-10-06 2007-09-26 Schering Corp Pirazolpirimidinas como inhibidores de protein quinasas
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB0616747D0 (en) * 2006-08-24 2006-10-04 Astrazeneca Ab Novel compounds
CN101611012B (zh) 2006-12-27 2012-11-14 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹啉衍生物
CN103588704B (zh) * 2007-03-16 2016-09-14 斯克里普斯研究学院 粘着斑激酶抑制剂
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
WO2009004329A1 (en) 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
BR112014010938A2 (pt) 2011-11-09 2017-05-16 Cancer Res Tech Ltd compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico
MX358819B (es) 2012-05-15 2018-09-05 Cancer Research Tech Ltd 5-[[4-[[morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]am ino]pirazina-2-carbonitrilo y usos terapeuticos del mismo.

Also Published As

Publication number Publication date
KR20200038990A (ko) 2020-04-14
NZ702050A (en) 2016-08-26
KR102341637B1 (ko) 2021-12-21
IL235133A (en) 2017-03-30
ZA201408452B (en) 2016-08-31
US9663503B2 (en) 2017-05-30
EP2855448B1 (en) 2017-02-08
EP3210980B1 (en) 2024-04-03
JP2015520753A (ja) 2015-07-23
AU2017268508A1 (en) 2017-12-14
US10259806B2 (en) 2019-04-16
KR102635954B1 (ko) 2024-02-13
CN106279142B (zh) 2019-05-03
JP6027230B2 (ja) 2016-11-16
HK1203529A1 (en) 2015-10-30
BR112014026801A2 (pt) 2017-06-27
MX358819B (es) 2018-09-05
KR20240023685A (ko) 2024-02-22
AU2017268508B2 (en) 2019-07-04
US20210276990A1 (en) 2021-09-09
RU2659786C2 (ru) 2018-07-04
KR102090792B1 (ko) 2020-03-18
PL2855448T3 (pl) 2017-09-29
AU2017268508C1 (en) 2019-10-17
CN104302635A (zh) 2015-01-21
HK1243408A1 (en) 2018-07-13
ES2624307T3 (es) 2017-07-13
KR20220151007A (ko) 2022-11-11
EP3210980A1 (en) 2017-08-30
CA2870837C (en) 2022-05-10
WO2013171470A1 (en) 2013-11-21
JP2017036314A (ja) 2017-02-16
DK2855448T3 (en) 2017-05-01
CN104302635B (zh) 2016-07-06
KR20150023252A (ko) 2015-03-05
EP2855448A1 (en) 2015-04-08
BR112014026801B1 (pt) 2022-03-03
KR102246265B1 (ko) 2021-04-29
US20150126471A1 (en) 2015-05-07
CA2870837A1 (en) 2013-11-21
CN106279142A (zh) 2017-01-04
SG11201407238VA (en) 2014-12-30
AU2013261605B2 (en) 2017-08-31
RU2014147105A (ru) 2016-07-10
AU2013261605A1 (en) 2014-11-13
MX2014012881A (es) 2015-04-08
JP6362652B2 (ja) 2018-07-25
IN2014DN09221A (enExample) 2015-07-10
KR20210047981A (ko) 2021-04-30
KR20210156333A (ko) 2021-12-24
US11787792B2 (en) 2023-10-17
US20180022739A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
ES2981584T3 (es) Proceso para la fabricación de 5-[[4-[[Morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]amino]pirazin-2-carbonitrilo
ES2826443T3 (es) Inhibidores de proteínas mutantes KRAS G12C
ES2856880T3 (es) Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
KR20210097715A (ko) 암 치료용 화합물 및 이의 사용 방법
CN110831933A (zh) 喹唑啉衍生物作为突变kras、hras或nras的调节剂
CN108779097A (zh) 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法
ES2709003T3 (es) Compuestos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrilo y su uso terapéutico
HK1243408B (en) Process for manufacturing 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)- 2-pyridyl]amino]pyrazine-2-carbonitrile
WO2025215188A1 (en) Therapeutic compounds and their use as inhibitors of pkmyt1
WO2025215187A1 (en) Therapeutic compounds and their use